Notice of Joint Research Agreement with Eurus Therapeutics Inc. for the Utilization of PPMX Antibody Library12/1TDnetPDF(188KB)
Notice of Extension of Investigator-Initiated Phase I/II Clinical Trial Period for PPMX-T003 in Aggressive NK-Cell Leukemia (ANKL)11/14TDnetPDF(203KB)
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses11/14TDnetPDF(103KB)
Non-consolidated Summary of Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 202611/14TDnetPDF(252KB)
Notice Regarding Execution of Joint Research Agreement between PPMX and ASKA Pharmaceutical for Creation of Novel Antibody Drugs11/5TDnetPDF(279KB)
Non-consolidated Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 20268/14TDnetPDF(282KB)
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses8/14TDnetPDF(108KB)